top of page
Search
LCA, early-onset severe retinal dystrophy: current management and clinical trials
RPE65-related LCA pivotal trials, . . . have paved the way for a new era of genetic treatments in ophthalmology.
Mar 12, 2021
Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease
Mutations in PRPF31 cause many more cases of RP than do mutations in RPE65, the gene targeted by Spark Tx Luxturna, Harvard researchers say.
Jul 6, 2020
All Posts
bottom of page